Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease MOUNTAIN

What this Trial Is About

Researchers are studying patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease RA-ILD to identify those at highest risk for disease progression. The study aims to better understand how RA-ILD develops over time by examining clinical signs, imaging results, and biological markers. The main hypothesis is that new imaging techniques and specific blood markers can help predict which patients will experience worsening of their lung disease. Participants will have blood samples collected for DNA, RNA, serum, and plasma analysis, as well as buccal cheek swabs. They will undergo clinical assessments including pulmonary function tests, 6-minute walk tests, and high-resolution computed tomography HRCT scans of the lungs, which are performed as part of their usual care. These tests and sample collections occur at baseline, every 4 months during clinic visits, and at yearly follow-ups over a two-year period. During the study, participants will complete questionnaires and have their medical history and current health status recorded. The research team will gather information on demographics, disease history, medications, lung function, imaging, and survival status. They will monitor participants over a five-year timeframe to evaluate imaging and blood-based markers. This includes observing changes in lung health and identifying profiles that may better predict disease progression.

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease